204 related articles for article (PubMed ID: 20976449)
21. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
Noguchi M; Moriya F; Koga N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
Cancer Immunol Immunother; 2016 Feb; 65(2):151-60. PubMed ID: 26728480
[TBL] [Abstract][Full Text] [Related]
22. Increased airway T regulatory cells in asthmatic subjects.
Smyth LJ; Eustace A; Kolsum U; Blaikely J; Singh D
Chest; 2010 Oct; 138(4):905-12. PubMed ID: 20453071
[TBL] [Abstract][Full Text] [Related]
23. Circulating gluten-specific FOXP3
Cook L; Munier CML; Seddiki N; van Bockel D; Ontiveros N; Hardy MY; Gillies JK; Levings MK; Reid HH; Petersen J; Rossjohn J; Anderson RP; Zaunders JJ; Tye-Din JA; Kelleher AD
J Allergy Clin Immunol; 2017 Dec; 140(6):1592-1603.e8. PubMed ID: 28283419
[TBL] [Abstract][Full Text] [Related]
24. Interaction with activated monocytes enhances cytokine expression and suppressive activity of human CD4+CD45ro+CD25+CD127(low) regulatory T cells.
Walter GJ; Evans HG; Menon B; Gullick NJ; Kirkham BW; Cope AP; Geissmann F; Taams LS
Arthritis Rheum; 2013 Mar; 65(3):627-38. PubMed ID: 23280063
[TBL] [Abstract][Full Text] [Related]
25. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
[TBL] [Abstract][Full Text] [Related]
26. Altered Suppressor Function of Regulatory T Cells in Type 1 Diabetes.
Aghili B; Amirzargar AA; Rajab A; Rabbani A; Sotoudeh A; Assadiasl S; Larijani B; Massoud A
Iran J Immunol; 2015 Dec; 12(4):240-51. PubMed ID: 26714416
[TBL] [Abstract][Full Text] [Related]
27. Higher frequency of regulatory T cells in granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts compared with G-CSF-primed peripheral blood grafts.
Zhao XY; Wang YT; Mo XD; Zhao XS; Wang YZ; Chang YJ; Huang XJ
J Transl Med; 2015 May; 13():145. PubMed ID: 25948100
[TBL] [Abstract][Full Text] [Related]
28. [Inhibition of CD4+ CD25+ regulatory T cells in chronic hepatitis B patients].
Zhang HH; Guo F; Fei R; Ma H; Cong X; Wei L; Chen HS
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(8):511-5. PubMed ID: 18649763
[TBL] [Abstract][Full Text] [Related]
29. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer.
Meidenbauer N; Harris DT; Spitler LE; Whiteside TL
Prostate; 2000 May; 43(2):88-100. PubMed ID: 10754524
[TBL] [Abstract][Full Text] [Related]
30. Increased frequency and suppressive activity of CD127(low/-) regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement.
Drennan S; Stafford ND; Greenman J; Green VL
Immunology; 2013 Nov; 140(3):335-43. PubMed ID: 23826668
[TBL] [Abstract][Full Text] [Related]
31. Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma.
Głowala-Kosińska M; Chwieduk A; Nieckula J; Saduś-Wojciechowska M; Grosicki S; Rusin A; Nowara E; Giebel S
Eur J Haematol; 2013 Aug; 91(2):122-8. PubMed ID: 23679234
[TBL] [Abstract][Full Text] [Related]
32. T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer.
Obradovic AZ; Dallos MC; Zahurak ML; Partin AW; Schaeffer EM; Ross AE; Allaf ME; Nirschl TR; Liu D; Chapman CG; O'Neal T; Cao H; Durham JN; Guner G; Baena-Del Valle JA; Ertunc O; De Marzo AM; Antonarakis ES; Drake CG
Clin Cancer Res; 2020 Jul; 26(13):3182-3192. PubMed ID: 32173650
[TBL] [Abstract][Full Text] [Related]
33. Isolation strategies of regulatory T cells for clinical trials: phenotype, function, stability, and expansion capacity.
Ukena SN; Höpting M; Velaga S; Ivanyi P; Grosse J; Baron U; Ganser A; Franzke A
Exp Hematol; 2011 Dec; 39(12):1152-60. PubMed ID: 21864487
[TBL] [Abstract][Full Text] [Related]
34. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
Powell DJ; Felipe-Silva A; Merino MJ; Ahmadzadeh M; Allen T; Levy C; White DE; Mavroukakis S; Kreitman RJ; Rosenberg SA; Pastan I
J Immunol; 2007 Oct; 179(7):4919-28. PubMed ID: 17878392
[TBL] [Abstract][Full Text] [Related]
35. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
Kantoff PW; Schuetz TJ; Blumenstein BA; Glode LM; Bilhartz DL; Wyand M; Manson K; Panicali DL; Laus R; Schlom J; Dahut WL; Arlen PM; Gulley JL; Godfrey WR
J Clin Oncol; 2010 Mar; 28(7):1099-105. PubMed ID: 20100959
[TBL] [Abstract][Full Text] [Related]
36. Low expressions of PD-L1 and CTLA-4 by induced CD4
Zhao L; Zhou X; Zhou X; Wang H; Gu L; Ke Y; Zhang M; Ji X; Yang X
Cytokine; 2020 Sep; 133():155119. PubMed ID: 32535334
[TBL] [Abstract][Full Text] [Related]
37. In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.
Akins EJ; Moore ML; Tang S; Willingham MC; Tooze JA; Dubey P
Cancer Res; 2010 May; 70(9):3473-82. PubMed ID: 20406970
[TBL] [Abstract][Full Text] [Related]
38. Single-Cell Sequencing Reveals the Transcriptome and TCR Characteristics of pTregs and
Hui Z; Zhang J; Zheng Y; Yang L; Yu W; An Y; Wei F; Ren X
Front Immunol; 2021; 12():619932. PubMed ID: 33868236
[TBL] [Abstract][Full Text] [Related]
39. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.
Kavanagh B; O'Brien S; Lee D; Hou Y; Weinberg V; Rini B; Allison JP; Small EJ; Fong L
Blood; 2008 Aug; 112(4):1175-83. PubMed ID: 18523152
[TBL] [Abstract][Full Text] [Related]
40. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.
Degl'Innocenti E; Grioni M; Capuano G; Jachetti E; Freschi M; Bertilaccio MT; Hess-Michelini R; Doglioni C; Bellone M
Cancer Res; 2008 Jan; 68(1):292-300. PubMed ID: 18172322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
